Keyword Analysis & Research: bgb 15025

clinicaltrials.gov

https://www.clinicaltrials.gov/ct2/show/NCT04649385

Dec 02, 2020 · BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Allocation: Non-Randomized Intervention Model: Sequential Assignment Estimated Enrollment : 240 participants Study Type : Interventional (Clinical Trial)

Allocation: Non-Randomized

Intervention Model: Sequential Assignment

Estimated Enrollment : 240 participants

Study Type : Interventional (Clinical Trial)

DA: 30 PA: 39 MOZ Rank: 50

beigenemedical.com

https://www.beigenemedical.com/CongressDocuments/Liu_BGB-15025_Preclinical_AACR_Poster_2022.pdf

BGB-15025 is currently in phase I clinicaltrial to treat patients with advanced solid tumor , both as a single agent and in combination with anti PD-1 antibody tislelizumab. 3 BGB-15025 is a potent and specific HPK1 kinase inhibitor HPK1 kinase domain. BGB-15025.

DA: 3 PA: 14 MOZ Rank: 91

cancer.gov

https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2021-03010

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors - NCT04649385

DA: 82 PA: 100 MOZ Rank: 22

mycancergenome.org

https://www.mycancergenome.org/content/drugs/bgb-15025/

Jul 30, 2018 · Bgb-15025 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating bgb-15025, 1 is phase 1 (1 open). Malignant solid tumor is the most common disease being investigated in bgb-15025 clinical trials [ 2 ]. Drug Details Drug Target (s) [ 2 ]: MAP4K1 References 1. National Cancer Institute.

DA: 47 PA: 98 MOZ Rank: 83

springer.com

https://adisinsight.springer.com/drugs/800059929

Oct 02, 2021 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. No New Molecular Entity Yes Available For Licensing Yes Highest Development Phases Phase I Solid tumours Most Recent Events 26 Mar 2021 BGB 15025 is available for licensing as of 26 Mar 2021. https://www.beigene.com/partnering

DA: 29 PA: 54 MOZ Rank: 84

businesswire.com

https://www.businesswire.com/news/home/20210310005134/en/BeiGene-Initiates-Phase-1-Clinical-Trial-for-HPK1-Inhibitor-BGB-15025

Mar 10, 2021 · BGB-15025 is an investigational hematopoietic progenitor kinase 1 (HPK1) inhibitor discovered and being developed by BeiGene. HPK1 is a key negative feedback regulator of T-cell receptor signaling,...

DA: 63 PA: 43 MOZ Rank: 47

beigenemedical.com

https://www.beigenemedical.com/CongressDocuments/Liu_BGB-15025_Preclinical_AACR_Abtract_2022.pdf

BGB-15025 potently inhibits HPK1 kinase activity in biochemical assay, with a 50% inhibitory concentration (IC50) of 1.04 nM under Km concentration of ATP. Consistently, BGB-15025 can potently reduce SLP76 phosphorylation and increase downstream ERK phosphorylation in a concentration dependent manner in T cells-based assay.

DA: 81 PA: 47 MOZ Rank: 55